Insights Into Acute Myeloid Leukemia (AML)

Perspectives of community physicians on the treatment of AML

Southwest – March 1, 2022

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Central – March 23, 2022

Faculty Chair

Courtney DiNardo, MD

MD Anderson Cancer Center, Houston, TX, USA

Southeast – June 30, 2022

Faculty Chair

Harry Erba, MD, PhD

Duke Cancer Center, Durham, NC, USA

Northeast – August 19, 2022

Faculty Chair

Eytan Stein, MD

Memorial Sloan Kettering Cancer Center< New York, NY, USA

TN Oncology – October 13, 2022

Faculty Chair

Harry Erba, MD, PhD

Duke Cancer Center, Durham, NC, USA

Midwest – September 17, 2022

Faculty Chair

Thomas Leblanc, MD

Duke Cancer Center, Durham, NC, USA

National – December 14, 2022

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Northwest – December 14, 2022

Faculty Chair

Elie Traer, MD

Oregon Health & Science University, Portland, OR, USA

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Portland, OR
  • TN Oncology

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Virtual series
  • National

More Information

  • Virtual series
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of AML
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.